Albuterol B P

證據等級: L5

預測適應症: 0 個

ALBUTEROL B.P.: Repurposing Evaluation — Insufficient Data for Full Assessment

One-Sentence Summary

ALBUTEROL B.P. (albuterol per British Pharmacopoeia specification) is a well-known beta-2 adrenergic agonist bronchodilator, widely used internationally for asthma and COPD management. However, the current Evidence Pack contains no TxGNN repurposing predictions, no Singapore regulatory registrations, and no retrievable safety data — meaning a substantive repurposing evaluation cannot be completed at this time. This report documents the data gaps and recommends a Hold decision pending remediation.

Quick Overview

Item	Content
Original Indication	Not available in regulatory records
Predicted New Indication	No prediction generated
TxGNN Prediction Score	N/A — No prediction available
Evidence Level	N/A — No supporting evidence retrieved
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Clinical Trial Evidence

Currently no related clinical trials registered for this candidate.

Note: Because no TxGNN repurposing target was predicted, no disease-specific trial search was performed.

Literature Evidence

Currently no related literature available for this candidate.

Note: Evidence retrieval requires a predicted indication as a search anchor. No search was executed.

Safety Considerations

Please refer to the package insert for safety information.

Drug-drug interaction query returned not found. Key warnings and contraindications were not retrievable from the current data pipeline. TFDA package insert parsing is listed as a Blocking data gap (DG001) and must be resolved before any safety-dependent decisions can be made.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for ALBUTEROL B.P. is critically incomplete — no TxGNN repurposing predictions were generated, the drug carries no Singapore HSA registrations, and both safety data and mechanism of action are flagged as unresolved data gaps. Without a predicted indication, no meaningful repurposing analysis can be conducted.

To proceed, the following is needed:

[DG001 — Blocking] Retrieve TFDA/HSA package insert PDF and parse warnings, contraindications, and approved indications
[DG002 — High] Query DrugBank API to obtain mechanism of action (MOA), pharmacological category, and DrugBank ID — the query log shows 1 result was returned but the drugbank_id field remains null; confirm and populate this field
Re-run TxGNN pipeline after DrugBank ID is confirmed — the empty predicted_indications array indicates the prediction step did not execute or matched no candidates; investigate whether the non-standard suffix "B.P." caused a normalisation failure
Confirm drug scope — verify whether "ALBUTEROL B.P." should be mapped to the INN "salbutamol" (the WHO INN), as HSA/international databases may catalogue this drug under the salbutamol entry, which may explain the zero-registration result
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.